Author Dr. Ben Green doesn’t just believe patients can be trusted to follow protocol from home, he believes that with the right technology and advice, clinical trials can happen at home, too.
Instead of requiring participants to travel for every appointment, we should be preparing participants and clinicians with the technology to make hybrid and decentralized trials work.
This article touches on how AliveCor’s KardiaMobile 6L ECG is a positive example of remote technology enabling more patient-centric, decentralized trials.
Key Takeaways
- Studies have found improved enrollment and retention among hybrid and decentralized clinical trials
- Many of the standard processes that take place on site can now be replaced by technology
- ECGs are often recommended in clinical trials for drug and disease monitoring, including cardiac, oncologic, and psychiatric medications
- Data collected via novel technologies must not only be high-quality and trusted but also delivered in familiar formats to trial researchers and clinicians
- AliveCor technology meets quality and trust standards
